Cerevel Therapeutics Holdings, Inc.
CERE
Rang in Aktien
#2821
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm... Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing treatments for a range of neuroscience disorders. The company boasts a robust pipeline of therapeutic candidates currently undergoing various phases of clinical evaluation. Key assets include emraclidine, a positive allosteric modulator (PAM) in Phase 1b trials for schizophrenia. Another PAM, Darigabat, is being assessed in a Phase 2 proof-of-concept study for drug-resistant focal onset seizures in epilepsy, as well as in a Phase 1 trial for acute anxiety. For Parkinson's disease, Cerevel is advancing Tavapadon, a selective dopamine D1/D5 partial agonist, through Phase 3 clinical trials for both early and late stages of the condition. A related compound, CVL-871, also a selective dopamine D1/D5 partial agonist, is in Phase 2a trials for dementia-related apathy. The company's portfolio further includes CVL-936, a selective dopamine D3-preferring antagonist in Phase I for substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist targeting major depressive disorder and substance use disorder; and CVL-047, a selective PDE4 inhibitor also aimed at major depressive disorder and substance use disorder. Beyond individual compounds, Cerevel is actively developing an M4 agonist program for psychosis and related indications, alongside an LRRK2 inhibitor program designed to address the progression of Parkinson's disease. Founded in 2018, Cerevel Therapeutics is headquartered in Cambridge, Massachusetts.
Aktienkurs
$44.96
Zuletzt synchronisiert: 2024-08-01
Marktkapitalisierung
$6.67B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Cerevel Therapeutics Holdings, Inc. (CERE)
Kategorie
Healthcare
Umsatz von Cerevel Therapeutics Holdings, Inc. (CERE)
Umsatz im Mar 2024 TTM: $8.25M
Laut den aktuellen Finanzberichten von Cerevel Therapeutics Holdings, Inc. beträgt der derzeitige Umsatz des Unternehmens (TTM) $8.25M. Im Jahr 2022 erzielte das Unternehmen einen Umsatz von 0.00 gleich wie dem Umsatz im Jahr 2021, der 0.00 betrug. Der Umsatz ist der Gesamtbetrag, den ein Unternehmen durch den Verkauf von Waren oder Dienstleistungen erzielt. Im Gegensatz zum Gewinn werden keine Ausgaben abgezogen.
Umsatzverlauf für Cerevel Therapeutics Holdings, Inc. von 2012 bis 2026
Umsatz am Ende jedes Jahres
| Jahr | Umsatz | ändert |
|---|---|---|
| 2026 (TTM) | $8.25M | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | -100.00% |
| 2015 | $2.72M | 13.14% |
| 2014 | $2.40M | -54.15% |
| 2013 | $5.24M | -2.38% |
| 2012 | $5.37M | 0.00% |
Umsatz vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Umsatz | Umsatzunterschied | Land |
|---|---|---|---|
| $12.62B | 152,996.05% |
US
|
|
| $2.23B | 26,919.16% |
US
|
|
| $15.74B | 190,832.90% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 72,920.70% |
NL
|
